D7407C00001- SOUNDTRACK-E

To assess safety and tolerability and determine the RP2D of AZD0486 (administered as IV or SC) as monotherapy and in combination with other anticancer agents across mature B-cell malignancies;À Incidence, nature, and severity of AEs/SAEs based on NCI CTCAE V5.0/ASTCT criteria; changes in laboratory data, and vital signs compared with baseline;À Incidence of DLTs;À Incidence and severity of AESIs;À Incidence and nature of study drug discontinuation, dose reduction, and dose delay due to AEs